A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD)
Status:
Not yet recruiting
Trial end date:
2024-12-22
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to:
- estimate vaccine response in rocatinlimab group vs placebo group, assessed using
antibody anti-tetanus response at Week 24
- estimate vaccine response in rocatinlimab group vs placebo group, assessed using
antibody anti-meningococcal response at Week 24
- characterize the safety and tolerability of rocatinlimab in the proposed population
- evaluate the immunogenicity of rocatinlimab